ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor

R. Zanotti, A. Ambrosetti, M. Lestani, P. Ghia, C. Pattaro, A. Remo, F. Zanetti, S. Stella, O. Perbellini, G. Prato, G. Guida, F. Caligaris-Cappio, F. Menestrina, G. Pizzolo, M. Chilosi

Research output: Contribution to journalArticlepeer-review

Abstract

Zeta-associated protein-70 (ZAP-70), mostly assessed by flow-cytometry (FC), recently emerged as reliable prognostic factor in chronic lymphocytic leukaemia (CLL) at presentation. We evaluated ZAP-70 expression in 156 CLL patients by immunohistochemistry (IHC) on formalin-fixed bone marrow (BM) biopsies at diagnosis. At presentation, 117 patients (75%) were with Binet stage A, 27 (17%) stage B and 12 (8%) stage C. Median follow-up was 61 months (range 6-242). ZAP-70 was expressed in neoplastic lymphocytes of 69 patients (44%). Concordance between ZAP-70 by IHC and ZAP-70 by FC, immunoglobulin heavy chain variable genes (IGHV) mutational status and CD38 expression was found in 41/46 (89%), 41/49 (80%) and in 60/88 (68%) tested cases, respectively. ZAP-70 expression significantly correlated with advanced Binet stage (B-C), diffuse BM infiltration, increased lactate dehydrogenase (LDH) and β2-microglobulin serum levels and lymphocyte doubling time

Original languageEnglish
Pages (from-to)102-109
Number of pages8
JournalLeukemia
Volume21
Issue number1
DOIs
Publication statusPublished - Jan 2007

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Fingerprint Dive into the research topics of 'ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor'. Together they form a unique fingerprint.

Cite this